Perinatal Hypoxia-Inducible Factor Stabilization Preserves Lung Alveolar and Vascular Growth in Experimental

Kellen Hirsch1,2, Elizabeth Taglauer3, Gregory Seedorf1,4,5

  • 1Pediatric Heart Lung Center and.

Insights

Antenatal inflammation increases bronchopulmonary dysplasia risk. Prolyl-hydroxylase inhibitor (PHi) therapy given before birth improved lung development and prevented pulmonary hypertension in a rat model.

Area of Science:

  • Neonatal Medicine
  • Pulmonary Medicine
  • Developmental Biology

Background:

  • Antenatal inflammation and placental dysfunction are linked to high bronchopulmonary dysplasia (BPD) risk in preterm infants.
  • The role of hypoxia-inducible factor (HIF) augmentation in preventing lung injury from intrauterine inflammation is debated.

Purpose of the Study:

  • To investigate if antenatal or postnatal prolyl-hydroxylase inhibitor (PHi) therapy can enhance lung HIF expression, preserve lung growth and function, and prevent pulmonary hypertension.
  • To evaluate PHi efficacy in a rat model of chorioamnionitis-induced BPD.

Main Methods:

  • Intrauterine endotoxin (ETX) administration to induce inflammation in pregnant rats.
  • Administration of PHi drugs (dimethyloxalylglycine or GSK360A) antenatally or postnatally.
  • Assessment of lung structure, function, vascularity, and right ventricle hypertrophy (RVH) in offspring.

Main Results:

  • Antenatal PHi therapy preserved lung alveolar and vascular growth and lung function.
  • PHi treatment prevented RVH and upregulated HIF-1a, HIF-2a, VEGF, and eNOS expression in the lungs.
  • Placental structure was also improved by antenatal PHi therapy.

Conclusions:

  • Hypoxia-inducible factor (HIF) augmentation via PHi therapy improves lung structure and function and prevents RVH after antenatal inflammation.
  • Antenatal PHi therapy shows promise for preventing BPD in infants exposed to intrauterine inflammation.
  • Further research into antenatal or postnatal PHi therapy is warranted for BPD prevention strategies.